<?xml version="1.0" encoding="UTF-8"?>
<p>There is no available evidence that supports discontinuation of biologic treatment of psoriasis for most patients simply because of the risk of infection [
 <xref ref-type="bibr" rid="CR24">24</xref>]. According to the results of randomized clinical trials of biological agents in psoriasis, the rates of nasopharyngitis and upper respiratory tract infections are similar to placebo [
 <xref ref-type="bibr" rid="CR25">25</xref>].
</p>
